EGFR and non-small cell lung carcinoma: It has been confirmed that epidermal growth factor receptor gene mutations are present in 35%–45% of NSCLC patients in China, and the 1st and 2nd generation EGFR complex kinase inhibitors are available for targeted treatment of NSCLC, which substantially prolongs the survival of patients [6].